JNK signaling as a target for anticancer therapy

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• JNKs (c-Jun N-terminal kinases) are mitogen-activated protein kinases regulating critical cellular processes like inflammation, proliferation, and apoptosis.
• Aberrant JNK signaling is implicated in the development and progression of various cancers, making JNKs promising therapeutic targets.
• Current JNK inhibitors often lack specificity, affecting multiple substrates and potentially causing cellular toxicity.

Purpose of the Study:

• To review and discuss strategies for developing selective JNK binding inhibitors.
• To elucidate the role of JNK signaling in the pathogenesis of solid and hematological malignancies.
• To address the need for specific JNK inhibitor design, considering the opposing roles of JNK1 and JNK2 in different cancers.

Main Methods:

• Literature review of existing studies on JNK signaling pathways.
• Analysis of different classes of JNK inhibitors, including ATP-competitive and non-competitive types.
• Examination of the involvement of JNK signaling in various cancer types.

Main Results:

• JNK signaling plays a significant role in cancer pathogenesis.
• Existing JNK inhibitors exhibit limitations in selectivity and can lead to toxicity.
• JNK1 and JNK2 have distinct, sometimes opposing, functions in cancer, necessitating tailored inhibitor strategies.

Conclusions:

• Targeting JNK signaling pathways offers a promising avenue for cancer therapy.
• Developing selective JNK inhibitors is crucial to enhance efficacy and reduce side effects.
• Further research into the specific roles of JNK isoforms in different malignancies is essential for rational drug design.